open access
Incidence and prevalence of lymphatic neoplasms in Poland 2009–2015 determined on analysis of National Health Fund data used in the ‘Maps of healthcare needs — database of systemic and implementation analyses’ project
Affiliations- Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
- Departement of Analysis and Strategies, Ministry of Health, Warsaw, Poland
- Social Insurance Department, Warsaw School of Economics, Warsaw, Poland
- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland
open access
Abstract
Introduction: The need for epidemiological data on blood neoplasms is driven by both systemic and scientific requirements. Due to the fact that all services provided to patients with these cancers in Poland are reported to the National Health Fund (NHF), the aim of this study was to try to use this data to estimate the incidence and prevalence of lymphatic neoplasms in Poland, as well as to determine overall survival (OS) in this group of patients. Materials and methods: The analysis was carried out as part of the ‘Maps of health needs — database of system and implementation analyses’ project, co-financed by the European Union through the European Social Fund under the Operational Program Knowledge Education Development. Results: The registered incidence of follicular lymphoma (FL) in 2014 was 1.74/100,000, whilst the registered prevalence was 15.56/100,000. The median OS of patients registered in the NHF system in 2009–2015 with an FL diagnosis was over 60 months, and the estimated 3- and 5-year OS rates were 76.6% and 68.8% respectively. In 2014, the incidence and prevalence of diffuse large B-cell lymphomas (DLBCL) was 3.76/100,000 and 27.48/100,000, respectively. The median OS was over 60 months, and the estimated 3- and 5-year OS rates were 68.7% and 61.1%, respectively. On the other hand, the incidence and prevalence of chronic lymphocytic leukemia (CLL) were 8.65/100,000/year and 38.28/100,000/year, respectively. The median OS was over 60 months, and the estimated 3- and 5-year OS rates were 77.8% and 64.8%, respectively. In the case of plasma cell myeloma (PCM), the registered incidence and prevalence were 4.92/100,000/year and 23.28/100,000/year, respectively. The median OS was 60 months, and the 3- and 5-year OS rates were 62.8% and 49.7%, respectively. Conclusions: The data reported to the National Health Fund in order to obtain reimbursement of medical services seems to be the most reliable data covering such a large population of patients. The results are similar to data from European and American registries for DLBCL and PCM. However, the FL and CLL data requires further verification.
Abstract
Introduction: The need for epidemiological data on blood neoplasms is driven by both systemic and scientific requirements. Due to the fact that all services provided to patients with these cancers in Poland are reported to the National Health Fund (NHF), the aim of this study was to try to use this data to estimate the incidence and prevalence of lymphatic neoplasms in Poland, as well as to determine overall survival (OS) in this group of patients. Materials and methods: The analysis was carried out as part of the ‘Maps of health needs — database of system and implementation analyses’ project, co-financed by the European Union through the European Social Fund under the Operational Program Knowledge Education Development. Results: The registered incidence of follicular lymphoma (FL) in 2014 was 1.74/100,000, whilst the registered prevalence was 15.56/100,000. The median OS of patients registered in the NHF system in 2009–2015 with an FL diagnosis was over 60 months, and the estimated 3- and 5-year OS rates were 76.6% and 68.8% respectively. In 2014, the incidence and prevalence of diffuse large B-cell lymphomas (DLBCL) was 3.76/100,000 and 27.48/100,000, respectively. The median OS was over 60 months, and the estimated 3- and 5-year OS rates were 68.7% and 61.1%, respectively. On the other hand, the incidence and prevalence of chronic lymphocytic leukemia (CLL) were 8.65/100,000/year and 38.28/100,000/year, respectively. The median OS was over 60 months, and the estimated 3- and 5-year OS rates were 77.8% and 64.8%, respectively. In the case of plasma cell myeloma (PCM), the registered incidence and prevalence were 4.92/100,000/year and 23.28/100,000/year, respectively. The median OS was 60 months, and the 3- and 5-year OS rates were 62.8% and 49.7%, respectively. Conclusions: The data reported to the National Health Fund in order to obtain reimbursement of medical services seems to be the most reliable data covering such a large population of patients. The results are similar to data from European and American registries for DLBCL and PCM. However, the FL and CLL data requires further verification.
Keywords
registered incidence, registered morbidity, overall survival probability, follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, plasma cell myeloma
About this articleTitle
Incidence and prevalence of lymphatic neoplasms in Poland 2009–2015 determined on analysis of National Health Fund data used in the ‘Maps of healthcare needs — database of systemic and implementation analyses’ project
Journal
Issue
Article type
Original research article
Pages
112-132
Page views
3455
Article views/downloads
329
DOI
10.5603/AHP.2022.0011
Bibliographic record
Acta Haematol Pol 2022;53(2):112-132.
Keywords
registered incidence
registered morbidity
overall survival probability
follicular lymphoma
diffuse large B-cell lymphoma
chronic lymphocytic leukemia
plasma cell myeloma
Authors
Ewa Lech-Marańda
Bożena Katarzyna Budziszewska
Tomasz Mikołajczyk
Barbara Więckowska
Janusz Dagiel
Wiesław Wiktor Jędrzejczak
References (20)- National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/ (September 1, 2021).
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–E386.
- Cancer Research UK. Cancer Statistics for the UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk (January 6, 2018).
- Contributions to Federal Health Reporting. Cancer in Germany 2011/2012. A joint publication of the Robert Koch Institute and the Association of Population-based Cancer Registries in Germany, 10th Edition, Robert Koch Institute, Berlin 2016. https://www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_chapters_2011_2012/cancer_germany_2011_2012.pdf?__blob=publicationFile ((January 6, 2018)).
- Budziszewska BK, Więckowska B, Lech-Marańda E, et al. Zachorowalność i chorobowość na nowotwory układu krwiotwórczego w Polsce (2009–2015) określone na podstawie analizy danych Narodowego Funduszu Zdrowia wykorzystanych w projekcie „Mapy potrzeb zdrowotnych — baza analiz systemowych i wdrożeniowych”. Hematologia. 2017; 8(2): 89–104.
- Więckowska B, Koń B, Dagiel J, Urbański F. Choroby onkologiczne w Polsce – wyniki modelu prognostycznego na lata 2015–2025. In: Więckowska B. ed. Proces leczenia w Polsce — analizy i modele. Tom I: Onkologia. Ministerstwo Zdrowia, Warszawa 2015: 292.
- http://www.mapypotrzebzdrowotnych.mz.gov.pl/mapy-dla-30-grup-chorob/ (September 1, 2021).
- R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2016. https://www.R-project.org/ (June 30, 2017).
- RStudio Team. RStudio: Integrated Development for R. RStudio. Inc., Boston 2015. http://www.rstudio.com/ (September 1,2021).
- Dowle M, Srinivasan A. data.table: Extension of ‘data.frame’. R package version 1.10.4, 2017. https://CRAN.R-project.org//package=data.table. (September 1,2021).
- Wickham H. ggplot2: elegant graphics for data analysis. Springer-Verlag, New York 2016. http://ggplot2.org (June 30, 2017).
- Therneau T. A package for survival analysis in S. version 2.38. 2015. http://CRAN.R-project.org/package=survival (June 30, 2017).
- Therneau T, Grambsch PM. Modeling survival data: extending the Cox model. Springer, New York 2000.
- Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116(19): 3724–3734.
- Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015; 112(9): 1575–1584.
- Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007; 110(2): 695–708.
- Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010; 116(20): e90–e98.
- Sant M, Minicozzi P, Mounier M, et al. EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014; 15(9): 931–942.
- Marcos-Gragera R, Allemani C, Tereanu C, et al. HAEMACARE Working Group. Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project. Haematologica. 2011; 96(5): 720–728.
- Chronic lymphocytic leukaemia (CLL) statistics. Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemiacll (January 6, 2018).